Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law - 2Surveys of Music Collections by Film Stars
- 3Seoul says sorry after unapproved drone flights into North Korea
- 4This Is Canada's Only Province Without Any Bears
- 5How we came to be: Scientists get first look at the evolution of early complex animals
- Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?
- Airport wait times won't return to normal until Congress reaches a deal to pay TSA. Here's why they still can't come to an agreement.
- Tatiana Schlossberg, JFK's granddaughter, dies at 35 after terminal cancer diagnosis
- Top Frozen yogurt Flavor: Cast Your Vote!
- No injuries after blast at pro-Israel centre in the Netherlands
- ‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
- Pick Your Number one Sort Of Music
- 10 Hints for an Effective New employee screening
- Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
